TTKHLTCARE · NSE
TTK Healthcare Limited
₹1,050
+0.10% (+₹1)
Prev. close
₹1,049
Volume
41,244
Delivery %
57.4%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About TTK Healthcare Limited
TTK Healthcare Limited engages in the animal welfare, consumer product, medical device, protective device, food, and other businesses in India. It operates through Animal Welfare, Consumer Products, Medical Devices, Foods, Protective Devices and Other segments. The Animal Welfare segment offers various feed supplements, liver correctives, fertility inducers, antibiotics, antiparasiticides, antispasmodics, cervical dilators, cocktail enzymes, etc. to veterinarians, dairy, poultry and aqua farmers, and pet parents. The Consumer Products segment is involved in the marketing and distribution of baby care products under the Woodward's Gripe water name; personal care products and cosmetics under the EVA name; home care products, such as scrubbers under the Good Home name; and air fresheners. The Medical Devices segment manufactures and markets artificial heart valves under the TTK Chitra name, as well as orthopedic implants and instruments for knee and hip replacements. The Protective Devices segment manufactures and markets sexual wellness products, including male contraceptives under the Skore brand name, and other allied products. The Foods segment engages in the manufacturing and marketing of food products, including papads under the Fryums name; and cereal, potato, rice, pulses, and corn-based products. The Others segment prints and publishes maps, atlases, guidebooks, and educational publications under the TTK brand name. The company was founded in 1928 and is headquartered in Chennai, India. TTK Healthcare Limited operates as a subsidiary of TT Krishnamachari & Co., Ltd.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. S. Kalyanaraman
Headquarters
Chennai
Employees
1,384
Website
ttkhealthcare.comExchange
View on NSE ↗Key stats
Market cap
₹1,482.27 Cr
P/E ratio (TTM)
20.4
Dividend yield
0.94%
EPS (TTM)
₹51.51
Beta (1Y · daily vs NIFTY 50)
0.67
Beta (5Y · monthly vs NIFTY 50)
1.03
Shares float
32.56 L
EPS · quarter ended Jun 2026
₹15.06
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹636.53 Cr | ₹599.24 Cr | ₹725.11 Cr | ₹752.79 Cr | ₹801.49 Cr | ₹857.28 Cr | |
| EBITDA | ₹52.99 Cr | — | ₹79.79 Cr | ₹99.93 Cr | ₹119.99 Cr | ₹94.25 Cr |
| ₹46.44 Cr | ₹41.59 Cr | ₹639.71 Cr | ₹62.84 Cr | ₹81.66 Cr | ₹65.68 Cr | |
| Diluted EPS | ₹32.87 | ₹29.43 | ₹452.72 | ₹44.47 | ₹57.79 | ₹46.48 |
Depreciation & amortisation, EBITDA have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹494.27 Cr | ₹558.55 Cr | ₹1,170.11 Cr | ₹1,200.59 Cr | ₹1,281.19 Cr | ₹1,328.74 Cr | |
| ₹19.14 Cr | ₹22.21 Cr | ₹27.33 Cr | ₹22.81 Cr | ₹24.22 Cr | ₹24.38 Cr | |
| Stockholders' equity | ₹294.65 Cr | ₹329.63 Cr | ₹953.38 Cr | ₹1,000.92 Cr | ₹1,065.05 Cr | ₹1,114.85 Cr |
Fixed assets, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹96.42 Cr | ₹45.00 Cr | ₹-24.81 Cr | ₹-4.94 Cr | ₹-3.98 Cr | ₹-21.15 Cr | |
| Investing cash flow | ₹-77.24 Cr | ₹-30.55 Cr | ₹31.69 Cr | ₹28.49 Cr | ₹20.10 Cr | ₹51.58 Cr |
| ₹-17.16 Cr | ₹-9.14 Cr | ₹-12.43 Cr | ₹-21.91 Cr | ₹-18.08 Cr | ₹-17.56 Cr | |
| Capital expenditure | ₹-1.73 Cr | ₹-6.49 Cr | ₹-11.70 Cr | ₹-10.38 Cr | ₹-12.84 Cr | ₹-5.80 Cr |
| End cash position | ₹9.55 Cr | ₹14.86 Cr | ₹9.32 Cr | ₹10.96 Cr | ₹9.01 Cr | ₹21.88 Cr |
Depreciation & amortization, Debt issued, Debt repaid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 74.56% |
| Public | 25.44% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| TTK Healthcare Limited | ₹1,482.27 Cr | ₹1,050 | 20.4 | 1.33 | 5.9% | 0.02 | +7.1% | -10.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
TTK Healthcare Q2 2026 Earnings: Revenue Rises 7.11% as EPS Comes in at ₹46.48 - Analyst Earnings Estimate
siam.in · 2 days ago